Optogenetics Circuit Discovery Holds 30 of 75 Studies While Only 3 Programmes Reach Humans or an IND Track and the Largest Disclosed Award Goes to Sonogenetics

InnoDexis has published its latest Innovation Intelligence Report covering optogenetics in its Nobel year, analyzing 75 screened research studies from 63 institutions in 13 countries between 9 January and 10 October 2026, alongside 3 valid corporate records from 1 May to 7 October 2026. The report reveals that optogenetics is settled as a discovery instrument and unproven as a therapy outside the eye: 30 of 75 studies use it purely for circuit discovery, every one in animals, while the only human efficacy data sit in the retina.

Key Findings

Circuit discovery is the largest thread. Thirty of 75 studies, 40 percent, use optogenetics to find which circuit causes a behaviour or disease phenotype, all in mouse, rat, fly, bird or worm models, and three route their finding to an approved drug: roflumilast at Groningen, levodopa at UC Irvine and ponesimod at UCLA.

The retina is the only clinical beachhead, and it is splitting in two. PIONEER, using ChrimsonR and camera goggles, reports 7 of 10 patients more light-sensitive and 6 of 10 clinically meaningful, while Restore Vision’s RV-001 reports 3 of 3 high-dose patients moving from no light perception to light perception within one month, without goggles.

The engineering frontier is longer wavelengths and fewer devices. Six studies work in amber, red or near-infrared light, Osaka Metropolitan University has engineered a dragonfly opsin sensitive around 720 nm toward near-infrared, and Opsin Biotherapeutics activates with low-power near-infrared via gold nanorods under a $2.35 million SBIR Phase II award.

Hardware for human light delivery is a commercial vacuum. Six research studies build interfaces, including DTU’s sub-0.5 mm mAxialtrode and KAIST’s IoT implant verified for four weeks in rats, while the corporate stream holds one research-instrument vendor and no human delivery device.

Rival modalities and funding sit elsewhere. Twelve adjacent studies use chemogenetics, sonogenetics or electroacupuncture, the Salk Institute’s ARPA-H award of up to $41.3 million is the largest disclosed figure, and no venture round is disclosed in either stream.

Strategic Insight and Trend Analysis

The defining structural finding is that optogenetics has become infrastructure rather than innovation. Thirty studies use it the way a cell biologist uses a pipette, and none is in a primate, so the commercial counterparty for the largest thread is a drug developer rather than an optogenetics company. Value is likely to be captured at two ends: with instrument vendors such as RWD Life Science, which reports support for more than 6,000 universities, and with whoever owns an activator that works in ambient or tissue-penetrating light.

The binding barrier is delivery, not discovery. Nineteen of 64 populated research-gap statements name translation to humans and 8 name long-term durability or biocompatibility, and the Huntington’s team spanning UC San Diego, the Max Planck Institute for Biological Intelligence and Würzburg states there is no non-invasive way to reach deep-brain neurons in people. Both clinical-stage therapy companies chose actuators that reduce the light-delivery burden, and no actor claims a standard for light dose or wavelength reporting.

The research and corporate streams do not touch. Zero organisations are verified parties in both, and the only overlaps are a funder, NIH/NINDS, and Oregon Health & Science University named in a Restore Vision release. Germany builds translation infrastructure, including the Else Kröner Fresenius Center for Optogenetic Therapies and SPARK-BIH’s €9.5 million across 22 projects, without a company in the corporate stream, while the United States contributes 31 of 75 studies and Japan pairs actuator research with Restore Vision.

Global and Industry Implications

For corporates and R&D teams, the open positions are the actuator and the delivery layer: seven actuator studies have no commercial owner and no disclosed IP, and six interface studies have no corporate human-delivery device. DTU’s mAxialtrode patent is in preparation, so an option is available before publication, while pharma teams can run the circuit thread as a repurposing screen.

For investors and capital allocators, the thesis is to back the removal of hardware, with RV-001, Opsin Biotherapeutics and Osaka’s near-infrared opsin the same bet at different stages, and to hedge with sonogenetics through SonoNeu. Due diligence should test durability beyond RV-001’s 168 days, PIONEER’s long-term follow-up and freedom to operate, which the extract cannot assess.

For policymakers and national innovation bodies, public money funds almost everything, with 39 of 75 screened studies naming government grants, yet no country funds chronic, human-grade light-delivery hardware. Named levers are a device scale-up call, a primate-validation programme linking circuit findings to marmoset capabilities, and a reporting convention for light dose and wavelength. Whether SPARK-BIH’s next round names an optogenetic project and whether ARPA-H funds an optogenetic counterpart are the watch items.

InnoDexis Statement

“Optogenetics has won its scientific argument and not yet started its commercial one — the question is whether light can reach the cell in a person without a device patients and regulators will not accept,” noted InnoDexis in its latest intelligence report.

Conclusion

With three valid corporate records, every commercial finding is a count within this extract rather than a market measure. The signals to watch are whether Opsin Biotherapeutics files an IND, with no non-retinal optogenetic IND by October 2028 invalidating pain as the second beachhead; whether Osaka’s near-infrared opsin is shown in mammalian tissue in vivo; whether SonoNeu announces financing or large-animal data; and whether any company announces a human light-delivery implant. The complete Engineering the Light Out Optogenetics Report October 2026 is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.

Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.

InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.